CLAIMS

1. Vinflunine pharmaceutical composition, characterized in that it is in the form of a stable and sterile aqueous solution of a water-soluble vinflunine salt at a pH of between 3 and 4.

2. Composition according to Claim 1, characterized in that the vinflunine salt is vinflunine ditartrate.

3. Composition according to Claim 2, characterized in that the composition consists of vinflunine ditartrate and water for an injectable preparation.

4. Composition according to Claim 1 or 2, characterized in that it comprises a pH buffer system in order to maintain the pH between 3 and 4.

5. Composition according to Claim 4, characterized in that the molarity of the pH buffer system is between 0.002 M and 0.2 M.

6. Composition according to either of Claims 4 and 5, characterized in that the pH buffer system consists of an acetic acid/sodium acetate buffer or a citric acid/sodium citrate buffer.

7. Composition according to any one of Claims 2 to 6, characterized in that the composition contains vinflunine ditartrate with a base vinflunine concentration of between 1 and 50 mg/ml, advantageously between 25 and 30 mg/ml and in particular 25 mg/ml.

8. Composition according to any one of Claims 2 to 7, characterized in that it corresponds to one of the

following formulations: 68.35 mg of vinflunine ditartrate qs 2 ml in water or 136.70 mg of vinflunine ditartrate qs 4 ml of water or 341.75 mg of vinflunine ditartrate qs 10 ml of water, the vinflunine ditartrate corresponding, respectively, to 50 mg of base vinflunine, 100 mg of base vinflunine and 250 mg of base vinflunine.

9. Composition according to any one of the preceding claims, characterized in that it remains stable for at least 36 months at 5°C±3°C.

10. Use of a composition according to any one of Claims 1 to 9, for the manufacture of a medicinal product for parenteral administration, advantageously via intravenous perfusion.

11. Use according to Claim 10, characterized in that the medicinal product is intended for treating cancer.

12. Process for preparing a composition according to any one of Claims 1 to 9, comprising the following successive steps:

- (a) dissolution of the vinflunine salt in water for injectable preparations,
- (b) optional addition of a pH buffer,
- (c) sterilization by filtration of the bulk solution,
- (d) aseptic distribution, under a nitrogen atmosphere, of the sterile composition obtained in step (c) in the container, advantageously chosen from glass phials, glass bottles and prefilled syringes.

13. Packaging container containing the composition according to any one of Claims 1 to 9.